Borderline personality disorder: who works on it

One card per institution. Pick a target or a country to narrow the list.

24 of 274 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIMH · F31

  Neurocognitive Characterization of Interpersonal Dysfunction in Borderline Personality Disorder

  Icahn School of Medicine at Mount Sinai· New York, United States· US$49,714 awarded in fiscal year 2026· until Sept 2029

• NIH NIMH · R01

  Antagonism and neurocomputational mechanisms of cooperation

  University of Pittsburgh at Pittsburgh· Pittsburgh, United States· US$810,435 awarded in fiscal year 2026· until Jun 2031

• NIH NIMH · R01

  Genetic risk discovery using WGS from a population-based resource of 10,000 suicide deaths with DNA

  Utah State Higher Education System--University of Utah· Salt Lake City, United States· US$768,981 awarded in fiscal year 2026· until Dec 2030

• NIH NIMH · F31

  Pathways of Personality Disorder: Combining Multiple Methods of Repeated Assessment Across Development and in Daily Life

  University of Houston· Houston, United States· US$38,127 awarded in fiscal year 2026· until Jul 2028

• NIH NIMH · K01

  Enhancing Clinical Terminology to Enable Precision Mental Healthcare

  University of Minnesota· Minneapolis, United States· US$185,789 awarded in fiscal year 2026· until May 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Disentangling psychological interventions for mental disorders into a taxonomy of active ingredients (DECOMPOSE)

  Universita Degli Studi di Padova· Padova, Italy· EU contribution €1,497,500· until Oct 2028

  The disease is named only in the funder's project summary, not in the title.

6 of 23 running projects, newest first. Listed amounts together: US$12.9m + €1.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adults

  NCT02225600· Icahn School of Medicine at Mount Sinai· Updated 2 Jul 2026

  “Study was halted during COVID pandemic. However, PI is currently reconnecting with a compounding pharmacy to re-establish supply of the oxytocin and updating cost estimates. We are hoping to resume the pilot work with oxytocin once it is clarified.”Registry text, quoted unchanged. Source

• Terminated

  Researching the Effectiveness of a Alivis, a Digital Health Application for Borderline Personality Disorder

  NCT06601907· Gaia AG· Updated 16 Mar 2026

  “An unplanned interim futility analysis was initiated due to differential dropout and participant feedback. The probability of achieving the pre-specified effect size was very low, and following DSMB review, the trial was terminated early.”Registry text, quoted unchanged. Source

• Withdrawn

  Representations of the Body's Interior in Adolescence

  NCT07407764· Centre Hospitalier Intercommunal Creteil· Updated 12 Feb 2026

  “Ethics committee refusal”Registry text, quoted unchanged. Source

• Withdrawn

  Role Of Sensitivity to neuroEndocrine Systems in Social Decisions

  NCT06018727· University of North Carolina, Chapel Hill· Updated 5 Jun 2024

  “Changed study design and it is no longer a clinical trial.”Registry text, quoted unchanged. Source

• Withdrawn

  Latent Toxoplasmosis in Females With Borderline Personality Disorder

  NCT03932656· Marie Ociskova· Updated 2 Apr 2024

  “Funding issues”Registry text, quoted unchanged. Source

• Withdrawn

  Epigenetic Changes in Psychotherapy of Adolescents With Borderline Personality Pathology

  NCT04095546· University Hospital, Basel, Switzerland· Updated 13 Sept 2022

  “personal changes in study team”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Short Integrative And Neurocognitive Therapy For Young Adults With Borderline Personality Disorder

  NCT05913544· Centre Hospitalier Universitaire de Nīmes· Source

• Repetitive Transcranial Magnetic Stimulation Versus Theta Burst Stimulation on Impulsivity, Emotional Dysregulation, and Non-Suicidal Self-Injury in Borderline Personality Disorder Patients

  NCT07919587· Ain Shams University· Source

• Combining Transcranial Magnetic Stimulation With Emotion Regulation Skills Training in Borderline Personality Disorder

  NCT07714005· Massachusetts General Hospital· Source

• Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder

  NCT06446765· Yale University· Source

• Affect-based Impulsivity in Borderline Personality Disorder

  NCT06880640· University of North Carolina, Chapel Hill· Source

• Cognitive Reappraisal Training for Borderline Personality (BPD)

  NCT06772831· Icahn School of Medicine at Mount Sinai· Source

• Brain Signal Training to Enhance Affect Down-regulation

  NCT06626789· Central Institute of Mental Health, Mannheim· Source

• A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

  NCT07001475· Boehringer Ingelheim· Source

• Real-time Experiences With Sleep Training Study

  NCT04507308· University of Utah· Source

• Testing a Peer-led Trauma-focused Intervention for Significant Others of Those With BPD

  NCT06135090· York University· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Mendelian Randomization Analysis 2
• Positron-Emission Tomography 2
• Magnetic Resonance Imaging 25
• Machine Learning 4
• Deep Learning 1
• Cohort Studies 7
• Genome-Wide Association Study 3

See which targets of this disease your abstract mentions, and go to the people working on them.